AN2 is continuing to assess the results before making a final decision on whether to study epetraborole in other settings. In the near term, the biotech is focusing on its boron chemistry platform, the source of research-stage programs in infectious disease and oncology.
As part of the pivot, AN2 is laying off half of its workforce. The biotech had 41 full-time employees at the end of February. Paul Eckburg, M.D., the chief medical officer at AN2, is among the people leaving the business. AN2, which ended March with $118.1 million, said it expects the cash runway of the slimmed-down company to extend through 2027.
https://www.fiercebiotech.com/biotech/an2-halves-headcount-stops-phase-3-trial-after-data-disappoint